Article
Developing a germline prostate cancer risk test incorporating rare and common variants, to inform clinical decisions: a route to precision oncology.
Genome medicine - 18 Apr 2026
Wakerell Sarah, Karlsson Questa, Merson Susan, Rageevakumar Reshma, Saunders Edward, Burns Dan, Brook Mark N, Dadaev Tokhir, Page Elizabeth C, Thomas Sarah, Taylor Natalie, Pope Jennifer, Cousins Shameela, McHugh Jana, Jones Ann-Britt, McVeigh Terri P, Bancroft Elizabeth K, Eeles Rosalind A, Kote-Jarai Zsofia
Abstract excerpt
BACKGROUND: Pathogenic germline variants in DNA damage response and repair (DDR) genes are established risk factors for prostate cancer (PrCa). Genetic testing for inherited PrCa is usually limited to small gene panels, even though common variants are recognised as harbouring a significant proportion of heritable risk. We have developed a genetic test to identify individuals with a genetic predisposition to PrCa...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.